Erschienen in:
11.10.2019 | ASO Author Reflections
ASO Author Reflections: Impact of Radiotherapy for Breast Cancer is Changing in the Modern Era
verfasst von:
Minoru Miyashita, MD, PhD, Naoki Niikura, MD, PhD, Yutaka Tokuda, MD, PhD
Erschienen in:
Annals of Surgical Oncology
|
Sonderheft 3/2019
Einloggen, um Zugang zu erhalten
Excerpt
The guidelines based on the retrospective data from 1990 to the early 2000s recommend postmastectomy radiotherapy (PMRT) for patients with clinically node-positive breast cancer treated with neoadjuvant chemotherapy (NAC). Whether PMRT improves survival in patients treated with NAC prior to mastectomy is unclear because no data from randomized, prospective trials are available. Some retrospective data for stage III breast cancer indicate that PMRT decreases locoregional recurrence (LRR), even for patients with a pathologic complete response (pCR) to NAC
1,
2. Other retrospective data suggest that patients who achieve a pCR with NAC exhibit low rates of LRR without PMRT
3,
4. In the current era, more effective systemic therapies, including anthracyclines, taxanes and trastuzumab, have been widely used. Regarding surgical procedures for axillary lymph nodes, sentinel lymph node biopsy is a standard for patients with clinically negative lymph nodes. Therefore, the significance of PMRT in modern treatments might change as systemic therapy becomes more powerful and axillary staging becomes more accurate. …
